Al-Hilli, Zahraa
Choong, Grace
Keeney, Michael G.
Visscher, Daniel W.
Ingle, James N.
Goetz, Matthew P.
Jakub, James W.
Funding for this research was provided by:
Mayo Clinic (P50CA116201, P30CA15083-43, P50CA116201)
Article History
Received: 8 April 2019
Accepted: 26 April 2019
First Online: 22 May 2019
Compliance with ethical standards
:
: Matthew P. Goetz has consulting or advisory role: Eli Lilly, Novartis, Context Therapeutics, and Sermonix. Research Funding: Eli Lilly, Pfizer. Patents, Royalties, Other Intellectual Property: Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; Methods and Materials for Using Butyrylcholinesterases to Treat Cancer. The other authors declare they have no competing interests and are in compliance with ethical standard.
: This study was reviewed and approved by Mayo Clinic institutional review board committee under study ID: 14-008981.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.